Expression levels of HMGA2 and CD9 and its clinicopathological significances in the benign and malignant lesions of the gallbladder
© Zou et al.; licensee BioMed Central Ltd. 2012
Received: 15 February 2012
Accepted: 21 May 2012
Published: 21 May 2012
The objective of this study was to investigate CD9 and HMGA2 expression and its clinicopathological significance in benign and malignant lesion tissues of the gallbladder.
The resected specimens of 108 cases of gallbladder adenocarcinoma, 46 cases of adjacent tissue, 15 cases of polyps and 35 cases of chronic cholecystitis were made into conventional paraffin-embedded sections, using the method of EnVision immunohistochemistry to stain HMGA2 and CD9.
HMGA2 expression of gallbladder adenocarcinoma was significantly higher than that of adenocarcinoma adjacent tissues (= 16.13, P <0.01), polyps (= 8.19, P <0.01) and chronic cholecystitis (= 21.41, P <0.01); but CD9 expression was the opposite (P <0.05 or P <0.01). The positive rate of HMGA2 expression from the cases that had well-differentiated adenocarcinoma, with the largest tumor diameter <2 cm, and without lymph node metastasis, and that did not invade the surrounding tissue was significantly lower than that of HMGA2 expression from the cases that had poorly differentiated adenocarcinoma, with the largest tumor diameter ≥2 cm, lymph node metastasis, and that invaded the surrounding tissues (P <0.05 or P <0.01). The positive rate of CD9 expression from the cases that had well-differentiated adenocarcinoma, with the largest tumor diameter <2 cm, and without lymph node metastasis, and that did not invade the surrounding tissue was significantly higher than that of CD9 expression from the cases that had poorly differentiated adenocarcinoma, with the largest tumor diameter ≥2 cm, lymph node metastasis, and which invaded the surrounding tissues (P <0.05 or P <0.01). The Kaplan-Meier survival analysis showed that after surgery, the survival period of HMGA2 expression-positive cases was significantly lower than that of HMGA2 expression- negative cases (P = 0.020), but the survival period of CD9 expression-positive cases was significantly higher than that of cases with CD9 expression-negative (P = 0.019). Cox multivariate regression analysis showed that the HMGA2 positive expression and/or CD9 negative expression was an important indicator reflecting the poor prognosis of gallbladder cancer.
The expression of HMGA2 and/or CD9 might be closely related to the carcinogenesis, clinical biological behaviors and prognosis of gallbladder adenocarcinoma.
Gallbladder cancer is the main malignancy occurring predominantly in older women. It accounts for nearly two-thirds of the biliary tract cancers, making it the most common primary biliary cancer and the fifth most common cancer of the gastrointestinal tract[1, 2]. More than 85% of gallbladder cancers belong to adenocarcinomas, and the rest, approximately 15%, are squamous, adenosquamous or undifferentiated carcinomas.
High mobility group protein A2 (high mobility group A2, HMGA2) is a recently discovered non-histone chromatin protein, which is closely related to tumorigenesis, invasion and metastasis of tumors, which have high expression in epithelial or interstitial malignant tumors, and have high extent and levels of expression, are dependent on the metastasis of malignant tumors, and have poor prognosis[3–8].
The CD9 protein, also known as migration − 1 (mobility related protein-1, MRP1), belongs to the transmembrane 4 superfamily (TM4SF), and is a glycoproteinthat could inhibit cell movement. Recent studies showed that the CD9 expression level was closely related to tumor progression, metastasis and invasion of tumors and that tumors with low CD9 expression were strongly prone to metastasis and invasion[9–15].
In this study, by application of EnVision immunohistochemistry, we investigated HMGA2 and CD9 expression levels in benign and malignant lesion tissues of the gallbladder and studied the clinicopathological significance of their expression in the prognosis of gallbladder tumors.
From June 1996 to June 2006, 108 cases of surgical specimens of gallbladder adenocarcinoma were collected in the Second Xiangya Hospital, Xiangya Hospital and Hunan Provincial People's Hospital. These included 31 male (28.7%) and 77 female cases (71.3%), with age ranges from 35 to 70 years (the mean age was 52.6 ± 11.2 years). Pathological types included 9 cases of adenoma canceration (8.2%, 7 well-differentiated cases and 2 moderately differentiated cases), 29 cases of well differentiated adenocarcinoma (26.9%), 29 cases of moderately differentiated adenocarcinoma (26.9%), 30 cases of poorly differentiated adenocarcinoma (27.8%), and 11 cases of mucinous adenocarcinoma (10.2%). Among 108 cases of gallbladder adenocarcinoma, there were 59 cases with tissues and organs surrounding the gallbladder damaged (54.6%); 59 cases with regional lymph node metastasis (54.6%); 58 cases with gallbladder stones (53.7%); 34 cases of radical surgical resection (31.5%), 48 cases of palliative surgery (44.4%), and 26 cases with disease inspection samples taken due to widespread metastasis (24.1%). The survival analysis data of 67 cases of 108 cases of gallbladder adenocarcinoma were obtained by means of letters and telephones. These included 20 cases with a survival period of ≥1 year and 47 cases with a survival period of <1 year. In 46 cases of gallbladder adenocarcinoma cancer tissues (from cancer ≥3 mm), selected from 108 cases gallbladder adenocarcinoma, according to the gallbladder epithelial dysplasia diagnostic criteria provided by Yamagiwa, there were 10 normal cases, 10 cases of mild dysplasia, 12 cases of moderate dysplasia and 14 cases of severe dysplasia. From June 1996 to June 2006, 15 polyps resected gallbladder specimens were collected in the Second Xiangya Hospital, including those of 5 males (33.3%) and 10 females (66.7%)( age ranges were 42 to 60 years with a mean age of 50.8 ± 9.6 years. For these cases, the maximum polyp diameter range was 8 to 15 mm. These specimens were all confirmed by pathologic examination to be adenomatous polyps. Of these, 10 cases were from normal to mild gallbladder epithelial dysplasia, and 5 cases were from moderate to severe dysplasia. Fifteen cases of simple chronic cholecystitis and 20 cases of chronic cholecystitis with cholelithiasis were selected from the Second Xiangya Hospital, as the chronic cholecystitis control group, including 15 male cases (42.9%) and 20 female (57.1%), with an age range of 31 to 58 years, with a mean age of (43.2 ± 12.4) years. The pathologic examination confirmed that in the 35 cases, there were 11 cases with normal gallbladder mucosa, 12 cases of mild dysplasia, 7 cases of moderate dysplasia and 5 cases of severe dysplasia. All the specimens were fixed in 4% formaldehyde and made into routine paraffin-embedded sections, and sliced 4 μm thick.
The mouse anti-human HMGA2 monoclonal antibodies were purchased from Abcam Ltd., (Cambridge, UK). The CD9 monoclonal antibodies were purchased from Dako Laboratories,(Carpinteria, CA, USA).
The EnVisionTM staining kits were purchased from Gene Company, (Basel, Switzerland).
All the experimental data were input using the SPPSS13.0 statistical package from SPSS Inc (Chicago,USA). The relationship between HMGA2 or CD9 expression and histological or clinical factors was analyzed by means of the χ2 test or Fisher's exact test, and a P-value <0.05 was statistically significant. The Kaplan-Meier method was used for univariate survival analysis (log-rank test), the Cox proportional hazards model was used for multivariate analysis, and Wald’s test was used to determine the 95% confidence interval.
HMGA2 and CD9 expression in the gallbladder of benign and malignant lesions
HMGA2 and CD9 expression in the gallbladder expression of benign and malignant lesions
Positive Number (%)
Positive Number (%)
Cancer adjacency tissues
The relationship between HMGA2 and CD9 expression and clinicopathological features of gallbladder cancer
The relationship between HMGA2 and CD9 expression and clinicopathological features of gallbladder cancer
Clinical and pathological features
Pathological types *
Tumor maximum diameter (cm)
Lymph node metastasis
Violations of the surrounding tissues
The relationship between HMGA2 and/or CD9 expression and survival time of patients with gallbladder cancer
Multivariate Cox regression analysis of survival ratio of 67 patients with gallbladder cancer
95% confidence interval
Adenoma / well-differentiated - / moderately differentiated - / poorly differentiated / mucinous adenocarcinoma
Tumor diameter (cm)
Lymph node metastasis
Violation of the surrounding tissues
The HMGA2 protein was found in the late 1980s, as one of the high mobility protein family members, encoded by the HMGA2 gene which is located on chromosome 12 q14, 15, and has a molecular weight of approximately 12 KD. HMGA2 has complex functions, and the current study focuses on its relationship with cancer. Previous studies have shown that HMGA2 gene expression in adult tissues was very low or had no expression, and was highly expressed in the early embryo and the epithelial or mesenchymal origin of malignant tumors, suggesting that the HMGA2 gene plays an important role in the growth of higher eukaryotes and in the proliferation and differentiation of malignant cells[17, 18]. Recently, some studies have shown that HMGA2 expression was closely related to the progression, invasion, metastasis and prognosis of a number of malignant tumors, and tumors with high HMGA2expression were highly malignant, and prone to invasive metastasis and poor prognosis[3–8]. However, there have not been reports about HMGA2 expression in the benign and malignant lesions of the gallbladder. Our data show that the HMGA2 positive expression ratio of gallbladder adenocarcinoma was significantly higher than that of the adjacent tissues, adenomatous polyps and gallbladder epithelium of chronic cholecystitis. Benign gallbladder epitheliums with HMGA2 positive expression appear to have moderate to severe dysplasia. The HMGA2 positive expression ratio of cases with well-differentiated adenocarcinoma, with the largest tumor diameter <2 cm, lymph node without metastasis and with organs which did not invade surrounding tissues was significantly lower than that of cases with poorly differentiated adenocarcinoma, the largest tumor diameter ≥2 cm, lymph node with metastasis and organs invading surrounding tissues. The Kaplan-Meier univariate survival analysis showed that after surgery, the survival time of cases with HMGA2-positive expression was significantly lower than that of cases with HMGA2-negative expression. The Cox multivariate analysis showed that HMGA2 expression was negatively correlated with the postoperative survival ratio, and was positively correlated with postoperative mortality, and was the evaluation factor for independent poor prognosis. These results suggest that the HMGA2 expression level of gallbladder adenocarcinoma was similar to that of other epithelial malignant tumors. HMGA2 also reflected progression and clinical behaviors of gallbladder cancer and was an important biological marker of prognosis. A high level of expression of HMGA2 showed poor prognosis.
CD9, also known as migration-associated protein −1 (MRP1), is a cell surface glycoprotein inhibiting cell movement, and belongs to the transmembrane 4 superfamily (TM4SF). After transfecting into cultured cells of non-hematopoietic cells, CD9 could inhibit the cell movement and, moreover, its inhibition is directly related with the quantity of CD9 expression, suggesting that CD9 was closely related with cell proliferation, cell motility, cell adhesion, invasion and metastasis of tumors. Recent studies on CD9 expression of lung, breast, pancreatic and colon cancers and other malignant tumors and its clinicopathological significance, suggested that CD9 expression was related to tumor metastasis, could inhibit tumor metastasis effect, and, that when the tumor had lymph node or hematogenous metastasis, the CD9 expression level was significantly reduced[9–15, 19]. Here, we investigated CD9 expression in the benign and malignant lesions of the gallbladder. Our data showed that the CD9-positive expression ratio of gallbladder cancer was significantly lower than that of the adjacent tissues, adenomatous polyps and gallbladder epithelium of chronic cholecystitis. The benign gallbladder epithelium CD9-negative expression showed moderate to severe dysplasia. The CD9 positive expression ratio of cases with well-differentiated adenocarcinoma, the largest tumor diameter <2 cm, lymph node without metastasis and organs, which did not invade surrounding tissues, was significantly higher than that of cases with the poorly differentiated adenocarcinoma, the largest tumor diameter ≥2 cm, lymph node with metastasis and organs invading surrounding tissues.
The Kaplan-Meier univariate survival analysis showed that after surgery the survival time of cases with CD9-positive expression was significantly higher than that of cases with CD9-negative expression. The Cox multivariate analysis showed that CD9 positive expression was positively correlated with the postoperative survival ratio, and was negatively correlated with postoperative mortality, and was the evaluation factor for independent poor prognosis. These results suggested that the CD9 expression level of gallbladder adenocarcinoma was similar to that of other epithelial malignant tumors. CD9 also reflected progression and clinical behaviors of the gallbladder cancer and was the important biological marker of prognosis. A high level expression of CD9 showed poor prognosis.
In the present study, our data showed that the expression of HMGA2 and/or CD9 might be closely related to carcinogenesis, clinical biological behaviors, and prognosis of gallbladder adenocarcinoma. The data also suggest the prognostic significance of HMGA2 and/or CD9 expression as a tumor biological marker in patients with gallbladder adenocarcinoma.
- Jones RS: Carcinoma of the gallbladder. Surg Clin North Am. 1990, 70: 1419-1428.PubMedGoogle Scholar
- Carriaga MT, Henson DE: Liver, gallbladder, extraHepatic bile ducts, and pancreas. Cancer. 1995, 75: 171-190. 10.1002/1097-0142(19950101)75:1+<171::AID-CNCR2820751306>3.0.CO;2-2.View ArticlePubMedGoogle Scholar
- Motoyama K, Inoue H, Nakamura Y, Uetake H, Sugihara K, Mori M: Clinical significance of high mobility group A2 in human gastric cancer and its relationship to let-7 microRNA family. Clin Cancer Res. 2008, 14: 2334-2340. 10.1158/1078-0432.CCR-07-4667.View ArticlePubMedGoogle Scholar
- Hristov AC, Cope L, Reyes MD, Singh M, Iacobuzio-Donahue C, Maitra A, Resar LM: HMGA2 protein expression correlates with lymph node metastasis and increased tumor grade in pancreatic ductal adenocarcinoma. Mod Pathol. 2009, 22: 43-49. 10.1038/modpathol.2008.140.PubMed CentralView ArticlePubMedGoogle Scholar
- Meyer B, Loeschke S, Schultze A, Weigel T, Sandkamp M, Goldmann T, Vollmer E, Bullerdiek J: HMGA2 overexpression in non-small cell lung cancer. Mol Carcinog. 2007, 46: 503-511. 10.1002/mc.20235.View ArticlePubMedGoogle Scholar
- Chiappetta G, Ferraro A, Vuttariello E, Monaco M, Galdiero F, De Simone V, Califano D, Pallante P, Botti G, Pezzullo L, Pierantoni GM, Santoro M, Fusco A: HMGA2 mRNA expression correlates with the malignant phenotype in human thyroid neoplasias. Eur J Cancer. 2008, 44: 1015-1021. 10.1016/j.ejca.2008.02.039.View ArticlePubMedGoogle Scholar
- Miyazawa J, Mitoro A, Kawashiri S, Chada KK, Imai K: Expression of mesenchyme-specific gene HMGA2 in squcell carcinomas of the oral cavity. Cancer Res. 2004, 64: 2024-2029. 10.1158/0008-5472.CAN-03-1855.View ArticlePubMedGoogle Scholar
- Malek A, Bakhidze E, Noske A: HMGA2 gene is a promising target for ovarian cancer silencing therapy. Int J Cancer. 2008, 123: 348-356. 10.1002/ijc.23491.View ArticlePubMedGoogle Scholar
- Nakamoto T, Murayama Y, Oritani K, Boucheix C, Rubinstein E, Nishida M, Katsube F, Watabe K, Kiso S, Tsutsui S, Tamura S, Shinomura Y, Hayashi N: A novel therapeutic strategy with anti-CD9 antibody in gastric cancers. J Gastroenterol. 2009, 44: 889-896. 10.1007/s00535-009-0081-3.View ArticlePubMedGoogle Scholar
- Zoller M: Tetraspanins: push and pull in suppressing and promoting metastasis. Nat Rev Cancer. 2009, 9: 40-55. 10.1038/nrc2543.View ArticlePubMedGoogle Scholar
- Bari R, Zhang YH, Zhang F, Wang NX, Stipp CS, Zheng JJ, Zhang XA: Transmembrane interactions are needed for KALL/CD82-mediated suppression of cancer invasion and metastasis. Am J Pathol. 2009, 174: 647-660. 10.2353/ajpath.2009.080685.PubMed CentralView ArticlePubMedGoogle Scholar
- Gesierich S, Paret C, Hidebrand D, Weitz J, Zgraggen K, Schmitz-Winnenthal FH, Horejsi V, Yoshie O, Herlyn D, Ashman LK, Zöller M: Colocalization of the tetraspanins, Co-029 and CD151, with integrins in human pancreatic adenocarcinoma: Impact on cell motility. Clin Cancer Res. 2005, 11: 2840-2852. 10.1158/1078-0432.CCR-04-1935.View ArticlePubMedGoogle Scholar
- Kanetaka K, Sakamoto M, Yamamoto Y, Yamasaki S, Lanza F, Kanematsu T, Hirohashi S: Overexpression of tetraspanin Co-029 in hepatocellular carcinoma. J Hepatol. 2001, 35: 637-642. 10.1016/S0168-8278(01)00183-0.View ArticlePubMedGoogle Scholar
- Mori M, Mimori K, Shiraishi T, Haraguchi M, Ueo H, Barnard GF, Akiyoshi T: Motility related protein 1 (MRP1/CD9) expression in colon cancer. Clin Cancer Res. 1998, 4: 1507-1510.PubMedGoogle Scholar
- Houle CD, Ding XY, Foley JF, Afshari CA, Barrett JC, Davis BJ: Loss of expression and altered localization of KAL1 and cd9 protein are associated with epithelial ovarian cancer progression. Gynecol Oncol. 2002, 86: 69-78. 10.1006/gyno.2002.6729.View ArticlePubMedGoogle Scholar
- Dalie M, Chenguan B: Observe and judge the results with immunohistochemical positive marks. J Clin Exp Pathol. 2003, 19: 557-559.Google Scholar
- Hock R, Furusawa T, Ueda T, Bustin M: HMG chromosomal proteins in development and disease. Trends Cell Biol. 2007, 17: 72-79. 10.1016/j.tcb.2006.12.001.PubMed CentralView ArticlePubMedGoogle Scholar
- Wunderlich V, Bottger M: High-mobility-group proteins and cancer: an emerging link. J Cancer Res Clin Oncol. 1997, 123: 133-140.PubMedGoogle Scholar
- Arihiro K, Kaneko M, Fujii S, Inai K: Loss of CD9 with expression of CD31 and VEGF in breast carcinoma, as predictive factors of lymph node metastasis. Breast Cancer. 1998, 5: 131-138. 10.1007/BF02966685.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.